NAVLE Primates

Other Small Mammal Multisystemic: Ebola Virus Disease Study Guide

📅 March 28, 2026 ⏱ 25 min read

Ebola virus disease (EVD) is a severe, often fatal viral hemorrhagic fever that affects non-human primates and humans.

Overview and Clinical Importance

Ebola virus disease (EVD) is a severe, often fatal viral hemorrhagic fever that affects non-human primates and humans. Caused by viruses in the genus Orthoebolavirus (family Filoviridae), EVD represents one of the most important zoonotic diseases for veterinary professionals working with primates or in biosafety settings.

Non-human primates (NHPs) serve as critical animal models for understanding human disease and are highly susceptible to Ebola virus infection. Understanding EVD pathogenesis in primates is essential for NAVLE candidates as it demonstrates key principles of viral hemorrhagic fever, zoonotic disease transmission, and biosafety protocols.

Species	Pathogenicity to Primates	Geographic Origin
Zaire ebolavirus (EBOV)	Highly pathogenic - uniformly lethal	Democratic Republic of Congo
Sudan ebolavirus (SUDV)	Highly pathogenic - high mortality	Sudan
Bundibugyo ebolavirus (BDBV)	Pathogenic - moderate mortality	Uganda
Reston ebolavirus (RESTV)	Pathogenic to NHPs, not humans	Philippines
Tai Forest ebolavirus (TAFV)	Mildly pathogenic	Ivory Coast

Etiology and Viral Classification

Viral Taxonomy and Structure

Ebola viruses belong to the genus Orthoebolavirus within the family Filoviridae. These are enveloped, negative-sense, single-stranded RNA viruses with characteristic filamentous morphology.

Pathogenic Ebolavirus Species

High-YieldZaire ebolavirus (EBOV) is the most virulent species and was responsible for the 2014-2016 West African outbreak. Reston virus is unique as it causes severe disease in non-human primates but appears non-pathogenic to humans.

Species	Susceptibility	Disease Course	Research Use
Cynomolgus macaques (Macaca fascicularis)	Highly susceptible	6-7 days to death, shorter than rhesus	Vaccine studies
Rhesus macaques (Macaca mulatta)	Highly susceptible	8-10 days to death, more prolonged	Therapeutic studies
African green monkeys (Chlorocebus aethiops)	Highly susceptible	Rapid progression, no rash development	Pathogenesis studies
Marmosets (Callithrix jacchus)	Highly susceptible	4-5 days to death, very rapid	Small animal model

Susceptible Non-Human Primate Species

Laboratory Research Models

Several NHP species serve as critical models for EVD research, with varying susceptibilities and disease progression patterns:

NAVLE TipRemember 'CHARM' for NHP susceptibility: Cynomolgus (vaccine studies), Hamadryas baboons, African green monkeys, Rhesus (therapeutics), Marmosets (small model). All show high mortality but different time courses.

Days Post-Infection	Clinical Signs	Laboratory Changes
3-4	Fever, anorexia, depression, mild dehydration	Viremia detectable, lymphopenia begins
5	Macular cutaneous rash, moderate dehydration, possible diarrhea	Peak viremia, thrombocytopenia, elevated liver enzymes
6-7	Recumbency, hypothermia, bleeding (nares, rectum), shock	Severe coagulopathy, renal dysfunction, metabolic acidosis

Pathophysiology and Multisystemic Effects

Cellular Tropism and Primary Targets

Ebola virus exhibits broad cellular tropism but shows particular affinity for specific cell types that drive the multisystemic pathology characteristic of EVD:

Dendritic cells and macrophages - early and sustained targets leading to immunosuppression
Hepatocytes - causing hepatic necrosis and elevated liver enzymes
Adrenal cortical cells - contributing to shock syndrome
Endothelial cells - causing vascular permeability and hemorrhage
Fibroblasts - particularly in lymphoid organs

Immune System Dysfunction

The hallmark of EVD pathogenesis is profound immunosuppression rather than excessive inflammation:

Lymphocyte Apoptosis: Widespread bystander lymphocyte death occurs early in infection, preventing adequate adaptive immune response development.

NK Cell Depletion: Rapid loss of natural killer cells compromises innate immunity and viral clearance.

Dendritic Cell Dysfunction: Infected dendritic cells fail to properly activate T-cell responses.

Organ System	Primary Lesions	Microscopic Features
Hepatic	Multifocal to coalescing hepatic necrosis	Acute inflammation, eosinophilic viral inclusions, fibrin microthrombi
Splenic	Lymphoid depletion and necrosis	White pulp necrosis, fibrin deposition, lymphocytolysis
Lymphoid	Lymphadenitis with follicular necrosis	Extensive lymphocyte apoptosis, fibroblastic reticular cell infection
Adrenal	Cortical necrosis	Acute necrosis of cortical cells, viral antigen positive

Clinical Signs and Disease Progression

Incubation Period and Early Signs

In laboratory NHP models, the incubation period ranges from 3-5 days post-infection, depending on challenge dose and route. Early clinical signs include:

Fever (often the first sign)
Malaise and depression
Anorexia
Hunched posture favoring abdomen

Progressive Clinical Manifestations

Parameter	Change	Clinical Significance
Total WBC	Initial leukocytosis then leukopenia	Neutrophilia followed by lymphocyte depletion
Lymphocytes	Severe lymphopenia	Bystander apoptosis, immunosuppression
Platelets	Progressive thrombocytopenia	Consumption coagulopathy
D-dimers	Markedly elevated	Disseminated intravascular coagulation

Gross and Histopathological Findings

Gross Necropsy Lesions

Gross pathological changes in terminal EVD cases include:

Petechial hemorrhages on skin and mucous membranes
Hepatomegaly with pale, mottled appearance
Splenomegaly with dark red discoloration
Lymph node enlargement (axillary, inguinal, mandibular)
Multifocal hemorrhagic pneumonia
Gastrointestinal hemorrhage

Histopathological Changes

High-YieldThe combination of hepatic necrosis, lymphoid depletion, and adrenal cortical damage creates the classic triad leading to coagulopathy, immunosuppression, and shock in EVD.

Enzyme/Marker	Change	Timing and Significance
ALT/AST	Markedly elevated	Late stage (days 5-6), indicates hepatocellular necrosis
BUN/Creatinine	Progressively elevated	Renal dysfunction more pronounced in cynomolgus vs rhesus macaques
Alkaline Phosphatase	Elevated	Hepatobiliary involvement
LDH	Markedly elevated	Tissue necrosis, useful early diagnostic marker

Laboratory and Hematological Changes

Hematological Parameters

Clinical Chemistry Abnormalities

NAVLE TipThe combination AST + LDH + CRP - Hemoglobin can outperform RT-PCR as an early laboratory indicator of EVD at 3 days post-infection in NHP models.

Method	Sample Type	Timing	Notes
RT-PCR	Blood, tissues	Fever onset, peak day 5	Gold standard, most sensitive
Antigen ELISA	Blood	Acute phase	Lower sensitivity than RT-PCR
IgM ELISA	Serum	Days following symptom onset	Survivors only
Virus isolation	Blood, tissues	Early phase	Vero E6 cells, BSL-4 required

Diagnostic Methods and Biosafety

Laboratory Diagnosis

Diagnosis of EVD in non-human primates requires BSL-4 laboratory facilities and specialized expertise. Key diagnostic methods include:

Biosafety and Containment

Critical biosafety considerations for handling suspected EVD cases in non-human primates:

BSL-4 containment required for all live virus work
Personal protective equipment: positive pressure suits
No direct contact with animals - remote monitoring when possible
Immediate euthanasia and necropsy protocols in BSL-4 setting
Staff health monitoring for 21 days post-exposure

Route	Mechanism	Risk Factors
Direct contact	Blood, body fluids, tissues from infected animals	Veterinary procedures, necropsy, laboratory work
Mucosal exposure	Conjunctival, oral, nasal contact with contaminated fluids	Dose-dependent lethality, natural infection route
Parenteral	Needlestick, surgical injuries, broken skin contact	Highest risk route, uniform lethality
Aerosol	Respiratory droplets from infected animals	Laboratory exposure, necropsy procedures

Transmission and Zoonotic Considerations

Natural Reservoir and Ecology

The natural reservoir for Ebola virus remains incompletely defined, but evidence strongly suggests:

Fruit bats (Pteropodidae family) as primary reservoir hosts
Bats remain asymptomatic while maintaining viral replication
Non-human primates are accidental hosts, not reservoir species
High mortality in NHPs indicates they are not adapted hosts

Transmission Pathways

High-YieldThe 1989 Reston ebolavirus outbreak in Virginia laboratory monkeys demonstrated viral transmission between NHPs in captivity and potential human exposure without clinical disease development.

Approach	Intervention	Rationale
Supportive Care	IV fluids, electrolyte replacement, nutritional support	Maintain hemodynamic stability and organ function
Monoclonal Antibodies	ZMapp, REGN-EB3, mAb114	Neutralizing antibodies targeting viral glycoprotein
Antiviral Drugs	Remdesivir, GS-5734	RNA polymerase inhibition
Vaccines	ERVEBO (rVSV-ZEBOV), prophylactic	Pre-exposure prophylaxis for at-risk personnel

Treatment and Management Approaches

Therapeutic Options

Currently, treatment for EVD in non-human primates remains primarily supportive, with experimental therapeutics under investigation:

Management of Suspected Cases

Immediate response protocols for suspected EVD in non-human primate facilities:

Immediate isolation and quarantine of affected animals
Notification of appropriate regulatory authorities
Implementation of enhanced biosecurity measures
Contact tracing and monitoring of exposed personnel
Environmental decontamination protocols

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →